These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34152439)

  • 21. Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
    Su X; Jin K; Guo Q; Xu Z; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
    Br J Cancer; 2024 Mar; 130(5):852-860. PubMed ID: 38212482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
    Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
    Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis.
    Koll FJ; Banek S; Kluth L; Köllermann J; Bankov K; Chun FK; Wild PJ; Weigert A; Reis H
    J Transl Med; 2023 Feb; 21(1):124. PubMed ID: 36793050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD19
    Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
    Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
    Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
    [No Abstract]   [Full Text] [Related]  

  • 28. Integration of CD4
    Liu G; Jin K; Liu Z; Su X; Xu Z; Li B; Xu J; Liu H; Chang Y; Zhu Y; Xu L; Wang Z; Wang Y; Zhang W
    Cancer Sci; 2024 Apr; 115(4):1306-1316. PubMed ID: 38402640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.
    Wang Y; Song W; Feng C; Wu S; Qin Z; Liu T; Ye Y; Huang R; Xie Y; Tang Z; Wang Q; Li T
    J Transl Med; 2024 Oct; 22(1):900. PubMed ID: 39367493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer.
    Wu S; Nitschke K; Worst TS; Fierek A; Weis CA; Eckstein M; Porubsky S; Kriegmair M; Erben P
    J Exp Clin Cancer Res; 2020 Dec; 39(1):288. PubMed ID: 33334367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
    Shao F; Jin K; Li B; Liu Z; Zeng H; Wang Y; Zhu Y; Xu L; Xu J; Wang Z; Chang Y; Zhang W
    Urol Oncol; 2023 Oct; 41(10):433.e9-433.e18. PubMed ID: 37625906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
    Xie H; Zhu Y; Zhang J; Liu Z; Fu H; Cao Y; Li G; Shen Y; Dai B; Xu J; Ye D
    BMC Cancer; 2018 May; 18(1):590. PubMed ID: 29793447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The tumour-associated stroma correlates with poor clinical outcomes and immunoevasive contexture in patients with upper tract urothelial carcinoma: results from a multicenter real-world study (TSU-01 Study).
    Xu L; Zhong W; Li C; Hong P; Xia K; Lin R; Cheng S; Wang B; Yang M; Chen J; Ma L; Li X; Zhou L; Huang J; Lin T
    Br J Cancer; 2023 Jan; 128(2):310-320. PubMed ID: 36396819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating molecular subtype and CD8
    Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Liu H; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Zhang W
    Cancer Immunol Immunother; 2024 Mar; 73(4):66. PubMed ID: 38430246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer.
    Nitschke K; Worst TS; von Rhade SM; Thaqi B; Neuberger M; Wessels F; Weis CA; Porubsky S; Gaiser T; Kriegmair M; von Hardenberg J; Weidenbusch M; Erben P; Nuhn P
    Urol Oncol; 2021 Aug; 39(8):499.e1-499.e8. PubMed ID: 34134925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
    Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
    Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
    Li H; Lu H; Cui W; Huang Y; Jin X
    Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer.
    Wang JT; Li H; Zhang H; Chen YF; Cao YF; Li RC; Lin C; Wei YC; Xiang XN; Fang HJ; Zhang HY; Gu Y; Liu X; Zhou RJ; Liu H; He HY; Zhang WJ; Shen ZB; Qin J; Xu JJ
    Ann Oncol; 2019 Feb; 30(2):266-273. PubMed ID: 30445581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.